Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

NCT03575598 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma, Head And Neck
Squamous Cell Carcinoma Mouth
Squamous Cell Carcinoma of the Oral Cavity

Interventions

DRUG: Sitravatinib
BIOLOGICAL: Nivolumab

Sponsor

University Health Network, Toronto

Collaborators

[object Object]